{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T12:56:12Z","timestamp":1783947372814,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.acuroe.2024.05.004","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T15:37:41Z","timestamp":1715355461000},"page":"555-564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Use of Bladder Epicheck\u00ae in the follow-up of non-muscle-invasive Bladder cancer: A systematic literature review"],"prefix":"10.1016","volume":"48","author":[{"given":"J.","family":"Ca\u00f1o Velasco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Artero Fullana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Polanco Pujol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lafuente Puentedura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.D.","family":"Subiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Arag\u00f3n Chamizo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Moralejo G\u00e1rate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hern\u00e1ndez Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuroe.2024.05.004_bib0005","unstructured":"Cancer Today - IARC. Estimated number of new cases in 2020, worldwide, both sexes, all ages. 2021 [Accessed Oct 2023]. Available from: https:\/\/gco.iarc.fr\/today\/online-analysis-table."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0010","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","article-title":"Economic burden of bladder cancer across the European Union","volume":"69","author":"Leal","year":"2016","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0015","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/CEOR.S274951","article-title":"Humanistic and economic burden of non-muscle invasive bladder cancer: results of two systematic literature reviews","author":"Lee","year":"2020","journal-title":"Clin Outcomes Res."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0020","unstructured":"Gontero P, Comp\u00e9rat E, Dominguez Escrig JL, Liedberg F, Mariappan P, Masson-Lecomte A, et al. European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). 2023 [Accessed Oct 2023]. Available from: https:\/\/uroweb.org\/guidelines\/non-muscle-invasive-bladdercancer\/chapter\/introduction."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0025","doi-asserted-by":"crossref","first-page":"329","DOI":"10.6004\/jnccn.2020.0011","article-title":"Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Flaig","year":"2020","journal-title":"J Natl Compr Canc Netw."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0030","unstructured":"EAU NMIBC Risk Calculator [Accessed Oct 2023]. Available from: https:\/\/nmibc.net\/."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1464-4096.2001.01899.x","article-title":"The community-based morbidity of flexible cystoscopy","volume":"89","author":"Burke","year":"2002","journal-title":"BJU Int."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0040","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.acuro.2019.03.001","article-title":"Urinary markers in the surveillance of non-muscle invasive bladder cancer. A literature review [Article in English, Spanish]","volume":"43","author":"Agreda Casta\u00f1eda","year":"2019","journal-title":"Actas Urol Esp (Engl Ed)."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0045","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.euo.2021.10.003","article-title":"European Association of Urology \u2013 Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Diagnostic accuracy of novel urinary biomarker tests in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis","volume":"4","author":"Laukhtina","year":"2021","journal-title":"Eur Urol Oncol."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0050","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.eururo.2019.04.035","article-title":"Evaluation of Cxbladder and adjudication of atypical cytology and equivocal cystoscopy","volume":"76","author":"Konety","year":"2019","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0055","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.euf.2022.02.006","article-title":"Reducing the frequency of follow-up cystoscopy in low-grade pTa non-muscle-invasive bladder cancer using the ADXBLADDER biomarker","volume":"8","author":"Roupr\u00eat","year":"2022","journal-title":"Eur Urol Focus."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0060","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1007\/s00345-021-03629-1","article-title":"Assessment of Xpert Bladder Cancer Monitor test performance for the detection of recurrence during non-muscle invasive bladder cancer follow-up","volume":"39","author":"Cancel-Tassin","year":"2021","journal-title":"World J Urol."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0065","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/bju.14673","article-title":"Diagnostic accuracy, clinical utility and influence on decision-making of a methylation urine biomarker test in the surveillance of non-muscle-invasive bladder cancer","volume":"123","author":"D\u2019Andrea","year":"2019","journal-title":"BJU Int."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2019.01237","article-title":"Validation of a novel, sensitive, and specific urine-based test for recurrence surveillance of patients with non-muscle-invasive bladder cancer in a comprehensive multicenter study","volume":"10","author":"Batista","year":"2019","journal-title":"Front Genet"},{"key":"10.1016\/j.acuroe.2024.05.004_bib0075","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1001\/jama.2017.19163","article-title":"Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement","volume":"319","author":"McInnes","year":"2018","journal-title":"JAMA."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0080","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0085","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cncy.22657","article-title":"DNA methylation analysis in urinary samples: a useful method to predict the risk of neoplastic recurrence in patients with urothelial carcinoma of the bladder in the high-risk group","volume":"131","author":"Pierconti","year":"2023","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0090","doi-asserted-by":"crossref","first-page":"108.e19","DOI":"10.1016\/j.urolonc.2021.11.013","article-title":"The bladder epicheck test and cytology in the follow-up of patients with non-muscle-invasive high grade bladder carcinoma","volume":"40","author":"Pierconti","year":"2022","journal-title":"Urol Oncol."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0095","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.eururo.2017.04.015","volume":"72","author":"Soukup","year":"2017","journal-title":"Eur Urol."},{"issue":"Suppl 1","key":"10.1016\/j.acuroe.2024.05.004_bib0100","doi-asserted-by":"crossref","first-page":"S388","DOI":"10.1016\/S0302-2838(23)00320-2","article-title":"Prospective study to evaluate the sensitivity and specificity of ADX-bladder and epicheck tests against urine cytology to detect early tumor recurrence in patients with non-muscle invasive bladder cancer","volume":"83","author":"Rodr\u00edguez Serrano","year":"2023","journal-title":"Eur Urol Suppl."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0105","doi-asserted-by":"crossref","first-page":"105.e11","DOI":"10.1016\/j.urolonc.2021.11.001","article-title":"Diagnostic performance of the Bladder EpiCheck methylation test and photodynamic diagnosis-guided cystoscopy in the surveillance of high-risk non-muscle invasive bladder cancer: a single centre, prospective, blinded clinical trial","volume":"40","author":"Cochetti","year":"2022","journal-title":"Urol Oncol."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0110","doi-asserted-by":"crossref","first-page":"131.e17","DOI":"10.1016\/j.urolonc.2020.06.018","article-title":"The combination cytology\/epichek test in non muscle invasive bladder carcinoma follow-up: Effective tool or useless expence?","volume":"39","author":"Pierconti","year":"2021","journal-title":"Urol Oncol."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0115","doi-asserted-by":"crossref","first-page":"3855","DOI":"10.3390\/jcm11133855","article-title":"Usefulness of the Urine Methylation Test (Bladder EpiCheck\u00ae) in follow-up patients with non-muscle invasive bladder cancer and cytological diagnosis of atypical urothelial cells-an institutional study","volume":"11","author":"Pe\u00f1a","year":"2022","journal-title":"J Clin Med."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0120","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/cncy.22246","article-title":"Comparison of 2 new real-time polymerase chain reaction-based urinary markers in the follow-up of patients with non-muscle-invasive bladder cancer","volume":"128","author":"Trenti","year":"2020","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0125","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00345-022-04252-4","article-title":"Bladder EpiCheck urine test in the follow-up of NMIBC: a cost analysis","volume":"41","author":"Hekman","year":"2023","journal-title":"World J Urol."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0130","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.acuro.2023.05.007","article-title":"Bladder Epicheck\u00ae for surveillance in high-risk non-muscle-invasive bladder cancer: initial experience and follow-up proposal","volume":"47","author":"Ca\u00f1o Velasco","year":"2023","journal-title":"Actas Urol Esp (Engl Ed)."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0135","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/j.clgc.2022.03.009","article-title":"The role of Bladder Epicheck test in follow-up of patients with non-muscle invasive bladder cancer","volume":"20","author":"Ragonese","year":"2022","journal-title":"Clin Genitourin Cancer."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0140","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.1016\/j.juro.2016.02.2496","article-title":"MP13-15 molecular urine cytology \u2013 bladder EPICHECK is a novel molecular diagnostic tool for monitoring of Bladder Cancer Patients","volume":"195","author":"Wasserstrom","year":"2016","journal-title":"J Urol."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0145","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.euo.2018.06.011","article-title":"Performance of the Bladder EpiCheck\u2122 methylation test for patients under surveillance for non-muscle-invasive bladder cancer: results of a multicenter, prospective, blinded clinical trial","volume":"1","author":"Witjes","year":"2018","journal-title":"Eur Urol Oncol."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0150","doi-asserted-by":"crossref","first-page":"e947","DOI":"10.1016\/S1569-9056(19)30689-X","article-title":"Performance of bladder EpiCheckTM for NMIBC monitoring\u2014updated results of a European multi-center study","volume":"18","author":"Lozano Palacio","year":"2019","journal-title":"Eur Urol Suppl."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0155","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/cncy.22152","article-title":"Diagnostic predictive value of the Bladder EpiCheck test in the follow-up of patients with non-muscle-invasive bladder cancer","volume":"127","author":"Trenti","year":"2019","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0160","doi-asserted-by":"crossref","first-page":"S994","DOI":"10.1016\/S0302-2838(21)01099-X","article-title":"P0723-Real World evidence of alternating cystoscopy\/cytology with bladder EpiCheck in NMIBC surveillance","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0165","doi-asserted-by":"crossref","first-page":"S993","DOI":"10.1016\/S0302-2838(21)01098-8","article-title":"Xpert\u00ae Bladder Cancer Monitor and Bladder Epicheck\u00ae in the follow up of patients affected by intermediate risk non muscle invasive bladder cancer (NMIBC): preliminary data","volume":"79","author":"D\u2019Elia","year":"2021","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0170","first-page":"2473","article-title":"Progressive increases in de novo methylation of CpG islands in bladder cancer","volume":"60","author":"Salem","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0175","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.03.163","article-title":"Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma","volume":"23","author":"Catto","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0180","doi-asserted-by":"crossref","first-page":"12489","DOI":"10.3390\/ijms241512489","article-title":"Bladder Epicheck test: a novel tool to support urothelial carcinoma diagnosis in urine samples","volume":"24","author":"Fiorentino","year":"2023","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0185","doi-asserted-by":"crossref","first-page":"e3118","DOI":"10.1016\/S1569-9056(19)33362-7","article-title":"Genomic subtypes of bladder cancer with distinct methylation profiles could be better identified by the Bladder EpiCheck test as compared to cystoscopy\/urine cytology","volume":"18","author":"Righetto","year":"2019","journal-title":"Eur Urol Suppl."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0190","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/his.13090","article-title":"Iatrogenic changes in the urinary tract","volume":"70","author":"Lopez-Beltran","year":"2017","journal-title":"Histopathology."},{"key":"10.1016\/j.acuroe.2024.05.004_bib0195","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/cncy.22539","article-title":"Impact of bacillus Calmette-Guerin intravesical therapy on the diagnostic efficacy of The Paris System for Reporting Urinary Cytology in patients with high-grade bladder cancer","volume":"130","author":"Hermans","year":"2022","journal-title":"Cancer Cytopathol."}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578624000647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578624000647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T11:27:22Z","timestamp":1727782042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578624000647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2173578624000647"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2024.05.004","relation":{},"ISSN":["2173-5786"],"issn-type":[{"value":"2173-5786","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of Bladder Epicheck\u00ae in the follow-up of non-muscle-invasive Bladder cancer: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2024.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2024.02.004","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}